Access to treatment-related and support services in methadone treatment programs

2007 ◽  
Vol 32 (1) ◽  
pp. 97-104 ◽  
Author(s):  
Nancy D. Berkman ◽  
Wendee M. Wechsberg
2002 ◽  
Author(s):  
Johannes van Dam ◽  
Sherry Hutchinson

As of December 2001, the number of people living with HIV/AIDS is estimated at 40 million, and most live in the developing world. Advances in the development and availability of antiretroviral (ARV) drugs have led to a paradigm shift in most of the industrialized world, where highly active ARV therapy has resulted in a significant reduction in the prevalence of AIDS-related morbidity and mortality. In most of the developing world, however, the focus of national programs and international support continues to be on prevention and care in the absence of ARV treatment. While the moral imperative to provide the best possible treatment for people with AIDS-related disease is widely recognized, national governments and donors have been reluctant to enter into this endeavor citing numerous concerns. Ministries of health and the international donor community need guidance on developing and implementing effective HIV/AIDS treatment programs. To explore and prioritize operations research questions about access to treatment for HIV/AIDS, the Horizons Program convened a two-day meeting of international researchers and program managers in Washington, DC, on June 12–13, 2001. This report presents the findings and recommendations discussed at the meeting.


2007 ◽  
Vol 97 (7) ◽  
pp. 1230-1232 ◽  
Author(s):  
Nabila El-Bassel ◽  
Louisa Gilbert ◽  
Elwin Wu ◽  
Mingway Chang ◽  
Jorge Fontdevila

2021 ◽  
Vol 12 ◽  
Author(s):  
Joseph Tay Wee Teck ◽  
Alexander Baldacchino ◽  
Lauren Gibson ◽  
Con Lafferty

Healthcare innovation has never been more important as it is now when the world is facing up to the unprecedented challenges brought by the COVID-19 pandemic. Within addictions services in Scotland, the priority has been to tackle our rising drug related death rate by maintaining and improving access to treatment while protecting frontline workers and managing operational challenges as a result of the pandemic. We present here a case study of five patients with opioid use disorder whose treatment represents a confluence of three important Medication Assisted Treatment (MAT) service innovations. The first was a low threshold drop in and outreach MAT service to rapidly and safely initiate opiate replacement therapy (ORT). The second was the provision of a microdosing regimen to enable same day induction to oral buprenorphine while minimizing the risk of precipitated opioid withdrawals and/or treatment disengagement. The third was rapid transitioning to an injectable long-acting buprenorphine depot which reduced unnecessary face to face patient contact and treatment non-adherence. This case study of five patients highlights the valuable role that buprenorphine microdosing can play in making induction to long-acting buprenorphine depot feasible to a broader range of patients, including those on a high dose methadone treatment regime.


2004 ◽  
Vol 23 (2) ◽  
pp. 15-31 ◽  
Author(s):  
W. M. Wechsberg ◽  
B. Flannery ◽  
J. J. Kasten ◽  
C. Suerken ◽  
L. Dunlap ◽  
...  

2016 ◽  
Vol 10 (3) ◽  
pp. 202-207 ◽  
Author(s):  
James M. Schuster ◽  
David Loveland ◽  
Meghna Parthasarathy ◽  
Nicole Maiolo ◽  
Alyssa Cilia ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document